Sector News

Novartis, GSK shake up executive ranks as overhaul continues

October 8, 2014
Life sciences
Six months after announcing a series of deals aimed at refocusing its R&D efforts, Novartis is starting to provide some glimpses of what the new company will look like–and who will and will not be leading it. 
 
Novartis confirmed today that in the first half of next year, it expects to close the three transactions it announced on April 22–the sale of its animal health unit to Eli Lilly for $5.4 billion, the sale of most of its vaccines to GlaxoSmithKline for $7.1 billion and the formation of a joint venture with GSK to market over-the-counter products. In a press release, the company said that George Gunn, the division head of Novartis Animal Health, will retire upon the closing of the Lilly deal, and Andrin Oswald, who helmed Novartis Vaccines, will be leaving “to pursue other opportunities.” 
 
One top exec is staying: Brian McNamara, division head for Novartis OTC, who will become head of the Americas and Europe for the newly formed joint venture, called GSK Consumer Healthcare. Simultaneous to McNamara’s appointment, GSK filed a notice to the Bombay Stock Exchange announcing that the company was promoting one of its senior executives in India, Zubair Ahmed, to head up the Asia Pacific, Middle East and Africa regions for the new OTC division, according to The Financial Express. 
 
Novartis CEO Joe Jimenez has long confessed to being a big fan of consumer health products, and the JV with Glaxo is designed to maintain the company’s presence in that industry while at the same time freeing up resources to concentrate on more profitable endeavors, such as developing cancer drugs. Novartis contributed $3.5 billion in assets to the new consumer joint venture, while Glaxo put in $6.5 billion. GSK has a 63.5% stake in the JV, leaving it with managerial control. 
 
The folks charged with managing GSK Consumer Healthcare have some big brands to back them up in a competitive market, including Excedrin, Panadol and Theraflu. But that doesn’t mean consumer health will continue to be a walk in the park for GSK. In July, GSK CEO Andrew Witty–who has embarked on a slimming-down campaign for his company much like Jimenez has done at Novartis–acknowledged that spinning off the consumer health division may ultimately be the best path forward.
 
As for Novartis, it’s continuing its bid to bulk up in oncology as it pulls away from vaccines and other slower-growing endeavors. Earlier this week, Novartis said it is designing new studies of two of its experimental cancer drugs and its newly approved ALK inhibitor Zykadia, all of which will be tested in combination with Bristol-Myers Squibb’s PD-1 drug Opdivo (nivolumab). And over the summer, Novartis’ personalized CAR-T cancer therapy development program won the FDA’s coveted “breakthrough” designation. 

By Arlene Weintraub

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.